子宫内膜癌诊断后就业中断研究
基于美国Truven MarketScan保险索赔数据库,纳入4381例诊断时全职或兼职工作的子宫内膜癌患者(18-63岁),评估诊断后一年内就业状态变化。21.7%患者出现就业变化,放化疗联合治疗者就业变化风险显著高于仅手术者(HR 1.34,95%CI 1.01-1.78)。
要点
- 约22%的子宫内膜癌患者诊断后一年内出现就业状态变化。
- 放化疗联合治疗是就业变化的独立预测因素(HR 1.34)。
- 多数患者诊断后继续工作,仅少数接受辅助治疗。
核心结论
- 约22%有雇主保险的子宫内膜癌患者诊断后出现就业状态变化。
- 放化疗联合治疗是就业变化的独立预测因素。
研究设计与样本
- 回顾性队列研究,数据来自美国Truven MarketScan保险索赔数据库。
- 纳入2009年1月至2017年12月诊断的18-63岁子宫内膜癌患者,共4381例诊断前12个月有全职或兼职工作者。
- 采用Cox比例风险模型评估治疗和人口学变量对就业状态变化的影响。
主要发现
- 诊断时中位年龄55岁,7.9%接受化疗,4.9%接受外照射放疗,4.1%接受放化疗。
- 21.7%(950例)患者诊断后一年内出现就业状态变化。
- 97.7%患者诊断前为全职工作。
- 多变量分析控制年龄、居住地区、合并症、保险计划类型和不良事件后,放化疗者就业变化风险比仅手术者高34%(HR 1.34,95%CI 1.01-1.78)。
临床怎么用
- 对接受放化疗的子宫内膜癌患者,应关注其就业状态变化风险。
- 临床咨询时可告知患者就业变化可能性,并提供支持资源。
局限性
- 研究基于保险索赔数据库,可能受编码准确性限制。
- 仅纳入有雇主保险的患者,结果外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oncologic treatment has been associated with unemployment. As endometrial cancer is highly curable, it is important to assess whether patients experience employment disruption after treatment. We evaluated the frequency of employment change following endometrial cancer diagnosis and assessed factors associated with it. METHODS: A cohort of patients 18-63 years-old who were diagnosed with endometrial cancer (January 2009-December 2017) were identified in the Truven MarketScan database, an insurance claims database of commercially insured patients in the United States. All patients who were working full- or part-time at diagnosis were included and all employment changes during the year following diagnosis were identified. Clinical information, including use of chemotherapy and radiation, were identified using Common Procedural Terminology codes, and International Statistical Classification of Diseases codes. Cox proportional hazards models incorporating measured covariates were used to evaluate the impact of treatment and demographic variables on change in employment status. RESULTS: A total of 4381 women diagnosed with endometrial cancer who held a full-time or part-time job 12 months prior to diagnosis were identified. Median age at diagnosis was 55 and a minority of patients received adjuvant therapy; 7.9% received chemotherapy, 4.9% received external-beam radiation therapy, and 4.1% received chemoradiation. While most women continued to work following diagnosis, 21.7% (950) experienced a change in employment status. The majority (97.7%) of patients had a full-time job prior to diagnosis. In a multivariable analysis controlling for age, region of residence, comorbidities, insurance plan type and presence of adverse events, chemoradiation recipients were 34% more likely to experience an employment change (HR 1.34, 95% CI 1.01-1.78), compared to those who only underwent surgery. CONCLUSION: Approximately 22% of women with employer-subsidized health insurance experienced a change in employment status following the diagnosis of endometrial cancer, an often-curable disease. Chemoradiation was an independent predictor of change in employment.
引用
- Nitecki R, Fu S, Lefkowits C, et al. Employment disruption following the diagnosis of endometrial cancer. Gynecol Oncol. 2020. PMID: 33183765. doi:10.1016/j.ygyno.2020.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。